These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 39059380)
1. Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype. Barrett JR; Pipini D; Wright ND; Cooper AJR; Gorini G; Quinkert D; Lias AM; Davies H; Rigby CA; Aleshnick M; Williams BG; Bradshaw WJ; Paterson NG; Martinson T; Kirtley P; Picard L; Wiggins CD; Donnellan FR; King LDW; Wang LT; Popplewell JF; Silk SE; de Ruiter Swain J; Skinner K; Kotraiah V; Noe AR; MacGill RS; King CR; Birkett AJ; Soisson LA; Minassian AM; Lauffenburger DA; Miura K; Long CA; Wilder BK; Koekemoer L; Tan J; Nielsen CM; McHugh K; Draper SJ Cell; 2024 Sep; 187(18):4964-4980.e21. PubMed ID: 39059380 [TBL] [Abstract][Full Text] [Related]
2. Estimation of PfRh5-based vaccine efficacy in asymptomatic Jun H; Mazigo E; Lee WJ; Louis JM; Syahada JH; Fitriana F; Heo J; Kim Y; Kwon B; Muh F; Lu F; Ahmed MA; Lee SJ; Na S; Chun W; Park WS; Hong M; Han JH; Kwon TH; Lee SU; Han ET; Todd J; Manjurano A; Kidima W; Han JH Front Immunol; 2024; 15():1495513. PubMed ID: 39624090 [TBL] [Abstract][Full Text] [Related]
3. Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5. Mangou K; Moore AJ; Thiam LG; Ba A; Orfanó A; Desamours I; Ndegwa DN; Goodwin J; Guo Y; Sheng Z; Patel SD; Diallo F; Sene SD; Pouye MN; Faye AT; Thiam A; Nunez V; Diagne CT; Sadio BD; Shapiro L; Faye O; Mbengue A; Bei AK Sci Rep; 2022 Nov; 12(1):19403. PubMed ID: 36371450 [TBL] [Abstract][Full Text] [Related]
4. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection. Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax. Cao Y; Hayashi CTH; Araujo MDS; Tripathi AK; Andrade AO; Medeiros JF; Vinetz J; Kumar N Vaccine; 2024 Aug; 42(21):126140. PubMed ID: 39033079 [TBL] [Abstract][Full Text] [Related]
6. Chahine ZM; Gupta M; Lenz T; Hollin T; Abel S; Banks C; Saraf A; Prudhomme J; Bhanvadia S; Florens LA; Le Roch KG Elife; 2024 Dec; 12():. PubMed ID: 39636094 [TBL] [Abstract][Full Text] [Related]
7. Vaccines and monoclonal antibodies: new tools for malaria control. Miura K; Flores-Garcia Y; Long CA; Zavala F Clin Microbiol Rev; 2024 Jun; 37(2):e0007123. PubMed ID: 38656211 [TBL] [Abstract][Full Text] [Related]
8. A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum. Beutler N; Pholcharee T; Oyen D; Flores-Garcia Y; MacGill RS; Garcia E; Calla J; Parren M; Yang L; Volkmuth W; Locke E; Regules JA; Dutta S; Emerling D; Early AM; Neafsey DE; Winzeler EA; King CR; Zavala F; Burton DR; Wilson IA; Rogers TF PLoS Pathog; 2022 Mar; 18(3):e1010409. PubMed ID: 35344575 [TBL] [Abstract][Full Text] [Related]
9. Vaccine candidate discovery for the next generation of malaria vaccines. Tuju J; Kamuyu G; Murungi LM; Osier FHA Immunology; 2017 Oct; 152(2):195-206. PubMed ID: 28646586 [TBL] [Abstract][Full Text] [Related]
10. A systems serology approach to identifying key antibody correlates of protection from cerebral malaria in Malawian children. Walker IS; Dini S; Aitken EH; Damelang T; Hasang W; Alemu A; Jensen ATR; Rambhatla JS; Opi DH; Duffy MF; Takashima E; Harawa V; Tsuboi T; Simpson JA; Mandala W; Taylor TE; Seydel KB; Chung AW; Rogerson SJ BMC Med; 2024 Sep; 22(1):388. PubMed ID: 39267089 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Diawara H; Healy SA; Mwakingwe-Omari A; Issiaka D; Diallo A; Traore S; Soumbounou IH; Gaoussou S; Zaidi I; Mahamar A; Attaher O; Fried M; Wylie BJ; Mohan R; Doan V; Doritchamou JYA; Dolo A; Morrison RD; Wang J; Hu Z; Rausch KM; Zeguime A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Dicko A; Duffy PE; Lancet Infect Dis; 2024 Dec; 24(12):1366-1382. PubMed ID: 39153490 [TBL] [Abstract][Full Text] [Related]